- Home
- VRXA vs IMRX Comparison
VRXA vs IMRX Comparison
Compare VRXA & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRXA | IMRX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.0M | 313.8M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRXA | IMRX |
|---|---|---|
| Price | $1.65 | $4.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 380.8K | ★ 632.6K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $3.86 |
| 52 Week High | $4.50 | $10.08 |
Technical Indicators
Market Signals| Indicator | VRXA | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 40.82 |
| Support Level | $1.27 | $4.49 |
| Resistance Level | $1.99 | $5.32 |
| Average True Range (ATR) | 0.21 | 0.20 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 52.05 | 13.54 |
Price Performance
Historical ComparisonAbout VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.